Detalhe da pesquisa
1.
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Cancer Sci
; 114(2): 546-560, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36285485
2.
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.
Invest New Drugs
; 40(2): 361-369, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35088212
3.
Dissociated response and clinical benefit in patients treated with nivolumab monotherapy.
Invest New Drugs
; 39(4): 1170-1178, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33566254
4.
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
BMC Cancer
; 21(1): 346, 2021 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794809
5.
Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report.
Invest New Drugs
; 38(4): 1192-1195, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31486987
6.
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Invest New Drugs
; 38(1): 211-218, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31784866
7.
Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
BMC Cancer
; 20(1): 104, 2020 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32028905
8.
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab.
Invest New Drugs
; 37(6): 1257-1265, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30937690
9.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Invest New Drugs
; 37(6): 1266-1273, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392549
10.
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.
Mol Cancer Ther
; 23(4): 564-576, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052760
11.
CD47 polymorphism for predicting nivolumab benefit in patients with advanced nonsmallcell lung cancer.
Oncol Lett
; 26(2): 364, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37545625
12.
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
NPJ Precis Oncol
; 7(1): 12, 2023 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702855
13.
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
Oncol Lett
; 24(5): 402, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36276492
14.
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Eur J Cancer
; 144: 317-325, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33385948
15.
Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
Sci Rep
; 11(1): 23677, 2021 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34880386
16.
Pneumonia Caused by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza Virus: A Multicenter Comparative Study.
Open Forum Infect Dis
; 8(7): ofab282, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34291119
17.
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Clin Lung Cancer
; 21(4): e315-e328, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32113737
18.
Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target.
Transl Lung Cancer Res
; 13(3): 689-693, 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38601438
19.
Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.
Cancer Chemother Pharmacol
; 84(2): 275-280, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31201490
20.
Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
Anticancer Res
; 39(5): 2561-2567, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31092453